Blog

Back to the future (of pharmacometrics) with Dr. Lawrence Lesko

Pharmacometrics uses mathematical models of biology, pharmacology, disease, and physiology to describe and quantify interactions…

Certara2015 年 12 月 1 日

Knowledge Base

9 Frequently Misunderstood Concepts in PK/PD Modeling

In teaching pharmacometrics, I've noticed that scientists have difficulty with certain PK/PD modeling concepts. Maybe…

Certara2015 年 11 月 3 日

Publication

Population PK & Dosing Implications for Cobimetinib in Cancer Patients

A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact…

Certara2015 年 11 月 1 日

Publication

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Bioavailability of orally administered drugs can be influenced by a number of factors including release…

Certara2015 年 11 月 1 日

Publication

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-release Tablets to Elderly and Young Subjects

Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol…

Certara2015 年 10 月 27 日

Knowledge Base

9 Things Your Boss Wishes You Knew About PK/PD Modeling

Over the course of my career, I have taught the theory and practical applications of PK/PD…

Certara2015 年 9 月 15 日

Publication

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

The published OS model and resultant simulations can be leveraged to support Phase II design…

Certara2015 年 9 月 1 日

Knowledge Base

Derivation for Logarithmic Trapezoidal AUC Calculation

Calculating area under the curve requires the use of two separate equations: one is follows…

Certara2015 年 8 月 5 日

Publication

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium Tuberculosis

Certara2015 年 7 月 23 日

Publication

Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients

Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…

Certara2015 年 7 月 23 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – PK/PD

Back to the future (of pharmacometrics) with Dr. Lawrence Lesko

9 Frequently Misunderstood Concepts in PK/PD Modeling

Population PK & Dosing Implications for Cobimetinib in Cancer Patients

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-release Tablets to Elderly and Young Subjects

9 Things Your Boss Wishes You Knew About PK/PD Modeling

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

Derivation for Logarithmic Trapezoidal AUC Calculation

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium Tuberculosis

Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients

订阅时事通讯

快捷链接

解决方案

联系我们